INO
Inovio Pharmaceuticals, Inc.2.3200
+0.0600+2.65%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
159.39MP/E (TTM)
-Basic EPS (TTM)
-2.72Dividend Yield
0%Recent Filings
8-K
10-Q
10-Q
Q2 FY2025 results
Inovio Pharmaceuticals narrowed its Q2 net loss to $23.5M from $32.2M y/y, with operating expenses dropping 31% to $23.1M on lower R&D for INO-3107 and other programs, while revenue stayed flat at nil. YTD net loss improved to $43.2M from $62.7M, driven by 30% lower operating costs and a $1.8M gain from warrant liability fair value changes, though EPS widened to $(1.12) from $(2.48) on higher shares outstanding (38.7M vs 25.2M). Cash burn eased to $47.7M YTD from $57.0M, leaving $47.5M in cash and equivalents at quarter-end, bolstered by $22.5M from a July offering extending runway into Q2 2026. No free cash flow disclosed in the 10-Q. Litigation with GeneOne settled in August, clearing a key overhang. Yet competition in DNA medicines intensifies.
8-K
Inovio cuts losses, advances BLA
Inovio Pharmaceuticals reported Q2 2025 net loss of $23.5 million, down from $32.2 million last year, as R&D expenses dropped to $14.5 million from $23.1 million amid focused spending on INO-3107. The company completed device testing and requested rolling BLA submission for INO-3107 in 2H25, targeting FDA acceptance by year-end and potential 2026 launch for RRP treatment. Cash stood at $47.5 million, bolstered by $22.5 million from a July stock offering, funding operations into Q2 2026. Long-term data showed sustained surgery reductions for RRP patients.
8-K
Inovio prices $25M offering
Inovio Pharmaceuticals inked an underwriting deal on July 2, 2025, to sell 14,285,715 shares of common stock plus Series A and B warrants at $1.75 each, targeting $25 million in gross proceeds. Net proceeds should hit $22.5 million after fees, with closing eyed for July 7, assuming no hiccups. Series A warrants expire in 12 months or 30 days post-FDA BLA acceptance for INO-3107; Series B last five years. Yet market volatility could derail the close.
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
GOVX
GeoVax Labs, Inc.
0.29-0.05
INAB
IN8bio, Inc.
1.50-0.10
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
INVA
Innoviva, Inc.
19.92-0.22
MRNA
Moderna, Inc.
29.89-0.03
NNVC
NanoViricides, Inc.
1.29+0.06
NVAX
Novavax, Inc.
6.54-0.04
REGN
Regeneron Pharmaceuticals, Inc.
746.36-6.26
VIR
Vir Biotechnology, Inc.
6.48-0.24